Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Baxter International Inc (BAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Baxter International Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Baxter International Inc trades at $22.08 (market cap $11.68B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.4× Baxter International Inc's market cap, and Baxter International Inc pays a 0.88% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BAX | |
|---|---|---|
Market Cap | $39.89B | $11.68B |
Sector | Health | Health |
52-Week High | $491.22 | $29.22 |
52-Week Low | $278.09 | $15.80 |
Enterprise Value | $38.15B | $19.35B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Baxter International (BAX) trades at $22.62, up 0.71% on the day, near the consensus price target of $22.67. The stock shows a bullish technical trend with recent earnings beats in Q1 2026, though profitability remains challenged with negative net income margins. Recent news highlights sustainability initiatives and upcoming Q2 2026 earnings, with analyst sentiment mixed but leaning hold.
Outlook hinges on operational turnaround amid margin pressures; upside exists if cost controls and innovation boost profits, but high debt and inconsistent cash flow pose risks. The stock offers speculative value for patient investors betting on recovery, but near-term volatility is likely until earnings stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
